<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Jeavons Syndrome - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Jeavons Syndrome</span>
        </nav>

        <header class="page-header">
            <h1>Jeavons Syndrome</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0015346" target="_blank">
                        MONDO:0015346
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Epilepsy</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Neurological Disorder</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Jeavons syndrome is a genetic generalized epilepsy characterized by eyelid myoclonia with or without absences, photosensitivity, and eyelid closure-induced seizures. Onset typically occurs in childhood and the condition often persists into adulthood with variable drug responsiveness.
            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">9</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">◆</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Eyelid Myoclonia with Absences (EMA)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">The most common presentation, characterized by eyelid myoclonia with or without absences.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30082241" target="_blank">PMID:30082241</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Criteria for Jeavons syndrome included all of the following: (1) eyelid myoclonia with or without absences..."</div>
                
                
                <div class="evidence-explanation">The criteria for diagnosing Jeavons syndrome include eyelid myoclonia with or without absences, supporting the statement&#39;s description.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37329145" target="_blank">PMID:37329145</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"There was consensus that generalized tonic-clonic and absence seizures are typically or occasionally seen in patients."</div>
                
                
                <div class="evidence-explanation">The consensus specifies that absence seizures can be typically or occasionally seen in patients with Jeavons syndrome, supporting the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Eyelid Myoclonia with Absences and Photosensitivity (EMA+)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Eyelid myoclonia with absences that are consistently provoked by photic stimulation.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35394968" target="_blank">PMID:35394968</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Epilepsy with eyelid myoclonia (EMA) is characterized by eyelid myoclonia, eyelid closure sensitivity, and photosensitivity."</div>
                
                
                <div class="evidence-explanation">This reference confirms that EMA, a defining feature of Jeavons Syndrome, includes photosensitivity as well as eyelid myoclonia and absences.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29722743" target="_blank">PMID:29722743</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Eyelid myoclonia with absences, generalized tonic-clonic seizures, and severe photosensitivity accompanied by eyelid myoclonia."</div>
                
                
                <div class="evidence-explanation">This case report discusses a patient with Jeavons Syndrome exhibiting eyelid myoclonia with absences and severe photosensitivity, supporting the subtype EMA+ described in the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Complex Genetic Predisposition</div>
                
                <div class="item-desc">A complex genetic basis involving multiple genes contributes to susceptibility.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30082241" target="_blank">PMID:30082241</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Jeavons syndrome is an underreported epileptic syndrome characterized by eyelid myoclonia, eyelid closure-induced seizures or electroencephalography paroxysms, and photosensitivity. Drug-resistant epilepsy is common, but the prognostic factors and clinical course leading to drug resistance have..."</div>
                
                
                <div class="evidence-explanation">The abstract discusses drug resistance without specifying a particular genetic basis, but it does imply complexity by mentioning the variability in response to treatments and presence of multiple seizure types.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neuronal Hyperexcitability</div>
                
                <div class="item-desc">Neurons in the brain exhibit increased excitability, particularly in response to visual stimuli.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Excitatory Glutamatergic Neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000679" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        chemical synaptic transmission
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007268" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21729035" target="_blank">PMID:21729035</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We observed two neurophysiologic findings in JS: (1) focal interictal EDs from posterior head region; and (2) predominant focal posterior ictal EDs preceding generalized EDs."</div>
                
                
                <div class="evidence-explanation">While the study supports an increased excitability of neurons in response to visual stimuli (such as photic stimulation), it does not specifically identify excitatory glutamatergic neurons as the key cell type involved.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31444362" target="_blank">PMID:31444362</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The transition from a preictal state to a generalized seizure leads to an abrupt increase in neural activity and connectivity, which is accompanied by a strong alteration in glia-neuron interactions and a massive increase in extracellular glutamate."</div>
                
                
                <div class="evidence-explanation">This study discusses neural activity and connectivity alterations and increased extracellular glutamate during seizures but does not specifically associate these findings with Jeavons Syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Disrupted Cortical Function</div>
                
                <div class="item-desc">Disruptions in normal brain function, especially in the visual cortex and thalamus, leading to seizures.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        visual perception
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007601" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Visual Cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000411" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        Thalamus
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001897" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21729035" target="_blank">PMID:21729035</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"JS has been proposed as idiopathic generalized epilepsy (IGE) because of normal posterior dominant background activity and paroxysmal generalized ictal epileptiform discharges (EDs). However, we noticed subtle occipital EDs preceding EM and interictal posterior EDs using digital video-EEG......"</div>
                
                
                <div class="evidence-explanation">The literature indicates involvement of the occipital cortex and mentions generalized epilepsy networks, which may include the thalamus. However, it does not explicitly support the claim that disruptions in the visual cortex and thalamus are the predominant mechanisms in Jeavons Syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29880477" target="_blank">PMID:29880477</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Largely accepted in the literature is the role the interconnections between the thalamus and cortex play in generalized epilepsy. However, thalamocortical involvement is less understood in focal epilepsy in terms of the effect of seizures on thalamocortical circuitry in the developing brain and..."</div>
                
                
                <div class="evidence-explanation">This study discusses the role of thalamocortical connections in generalized and focal epilepsy but does not provide specific information on Jeavons Syndrome or its mechanisms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Eyelid_Myoclonia[&#34;Eyelid Myoclonia&#34;]
    Impaired_Visual_Functioning_During_Episodes[&#34;Impaired Visual Functioning During Episodes&#34;]

    Eyelid_Myoclonia --&gt; Impaired_Visual_Functioning_During_Episodes

    style Eyelid_Myoclonia fill:#fef3c7
    style Impaired_Visual_Functioning_During_Episodes fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">7</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Eye<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Nervous System<span class="pill-count">(3)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Other<span class="pill-count">(3)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Eye
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Impaired Visual Functioning During Episodes
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000572" target="_blank">
                                Visual loss
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000572)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8270934" target="_blank">PMID:8270934</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Brief, typical absences occur with rapid eyelid myoclonia associated with retropulsive movements of the eyeballs and occasionally of the head. The seizures are of shorter duration than in childhood absence epilepsy, and are accompanied by less profound impairment of consciousness."</div>
                
                
                <div class="evidence-explanation">The rapid eyelid movements and retropulsive eye movements during seizures directly impair visual function during episodes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32554361" target="_blank">PMID:32554361</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Jeavons syndrome (JS) is mainly characterized by eyelid myoclonia with or without absences."</div>
                
                
                <div class="evidence-explanation">The characteristic eyelid myoclonia inherently causes transient visual impairment during episodes due to involuntary eyelid closure.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Eyelid Myoclonia
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0011149" target="_blank">
                                Absence seizure with eyelid myoclonia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0011149)</span>
                        </span>
                        
                    </div>
                    
                    
                    <div class="item-meta">
                        <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Impaired Visual Functioning During Episodes</span>
                        
                    </div>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32554361" target="_blank">PMID:32554361</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Jeavons syndrome (JS) is mainly characterized by eyelid myoclonia with or without absences."</div>
                
                
                <div class="evidence-explanation">The literature supports the neurologic diagnostic of eyelid myoclonia as a high frequency phenotype of Jeavons Syndrome (JS).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30685520" target="_blank">PMID:30685520</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Eyelid myoclonia, the most common seizure type in all 8 patients, were typically initiated by eating or other simple orofacial stimuli."</div>
                
                
                <div class="evidence-explanation">This study confirms that eyelid myoclonia is a common and significant phenotype of JS, reinforcing the diagnostic.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36216271" target="_blank">PMID:36216271</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"To the best of our knowledge, this is the first case of STAG2 encephalopathy fulfilling all electroclinical criteria for epilepsy with eyelid myoclonia and absences (EMA), formally named Jeavons syndrome (JS)."</div>
                
                
                <div class="evidence-explanation">It confirms the diagnostic frequency of eyelid myoclonia as a defining characteristic of JS.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Absences
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0011149" target="_blank">
                                Absence seizure with eyelid myoclonia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0011149)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15508923" target="_blank">PMID:15508923</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Eyelid myoclonia and absence."</div>
                
                
                <div class="evidence-explanation">The literature provides a title indicating a connection between eyelid myoclonia (a feature of Jeavons Syndrome) and absences, further supporting the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Generalized Tonic-Clonic Seizures
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0025190" target="_blank">
                                Bilateral tonic-clonic seizure with generalized onset
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0025190)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30082241" target="_blank">PMID:30082241</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"After a median follow-up of two years, 80% of patients had drug-resistant epilepsy and 70% experienced generalized tonic-clonic seizures."</div>
                
                
                <div class="evidence-explanation">The statement is partially supported because generalized tonic-clonic seizures occur in 70% of patients, which suggests a high frequency rather than &#39;occasional&#39;.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Mild Cognitive Impairment
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26492104" target="_blank">PMID:26492104</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"All participants completed neuropsychological evaluations. Statistical analyses revealed performance that was below average on measures of global IQ, processing speed and rote, verbal learning coupled with average nonverbal reasoning, and sustained attention. There was also evidence of impaired..."</div>
                
                
                <div class="evidence-explanation">The literature supports that there are cognitive impairments in Jeavons syndrome, but it does not explicitly classify these impairments as &#39;mild cognitive impairment&#39; (MCI) nor does it mention the frequency as &#39;occasional&#39;. The impairments are more specific and varied, making the statement partially correct but not completely accurate.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Photosensitivity
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Increased sensitivity to light stimulation, which can provoke seizures or eyelid myoclonia. A common finding in Jeavons syndrome.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30082241" target="_blank">PMID:30082241</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Jeavons syndrome is an underreported epileptic syndrome characterized by eyelid myoclonia, eyelid closure-induced seizures or electroencephalography paroxysms, and photosensitivity."</div>
                
                
                <div class="evidence-explanation">The abstract clearly states that photosensitivity is a characteristic feature of Jeavons syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Developmental Delays
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Mildly delayed motor, language, or social milestones in some patients, especially with early onset of seizures.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30082241" target="_blank">PMID:30082241</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"BACKGROUND: Jeavons syndrome is an underreported epileptic syndrome characterized by eyelid myoclonia, eyelid closure-induced seizures or electroencephalography paroxysms, and photosensitivity."</div>
                
                
                <div class="evidence-explanation">The abstract does not mention developmental delays or any developmental milestones in relation to Jeavons Syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30683501" target="_blank">PMID:30683501</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Jeavons Syndrome: An Overlooked Epilepsy Syndrome."</div>
                
                
                <div class="evidence-explanation">The abstract does not provide information on developmental delays or milestones in Jeavons Syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">9</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SYNGAP1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30541864" target="_blank">PMID:30541864</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Seizure types included eyelid myoclonia with absences (65%), myoclonic seizures (34%), atypical (20%) and typical (18%) absences, and atonic seizures (14%), triggered by eating in 25%."</div>
                
                
                <div class="evidence-explanation">This large cohort study of 57 SYNGAP1 patients found 65% had eyelid myoclonia with absences, demonstrating strong overlap with Jeavons syndrome phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34070602" target="_blank">PMID:34070602</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Based on this, four genes could be associated to this syndrome (SYNGAP1, KIA02022/NEXMIF, RORB, and CHD2)."</div>
                
                
                <div class="evidence-explanation">This review identifies SYNGAP1 as one of four candidate genes associated with eyelid myoclonia with absences (Jeavons syndrome).</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NEXMIF
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34070602" target="_blank">PMID:34070602</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Based on this, four genes could be associated to this syndrome (SYNGAP1, KIA02022/NEXMIF, RORB, and CHD2)."</div>
                
                
                <div class="evidence-explanation">This review identifies NEXMIF (KIAA2022) as one of four candidate genes associated with eyelid myoclonia with absences (Jeavons syndrome).</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    RORB
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34070602" target="_blank">PMID:34070602</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Based on this, four genes could be associated to this syndrome (SYNGAP1, KIA02022/NEXMIF, RORB, and CHD2)."</div>
                
                
                <div class="evidence-explanation">This review identifies RORB as one of four candidate genes associated with eyelid myoclonia with absences (Jeavons syndrome).</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CHD2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26262932" target="_blank">PMID:26262932</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Conversely, CHD2 could be responsible for a proper phenotype characterized by infantile-onset generalized epilepsy, intellectual disability, and photosensitivity, which might overlap with MAE, Lennox-Gastaut, Dravet, and Jeavons syndromes."</div>
                
                
                <div class="evidence-explanation">The literature indicates that CHD2 mutations may overlap with phenotypes seen in Jeavons Syndrome, but it does not specifically state a direct genetic association exclusive to Jeavons Syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34070602" target="_blank">PMID:34070602</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Based on this, four genes could be associated to this syndrome (SYNGAP1, KIA02022/NEXMIF, RORB, and CHD2)."</div>
                
                
                <div class="evidence-explanation">This review identifies CHD2 as one of four candidate genes associated with eyelid myoclonia with absences (Jeavons syndrome).</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CSNK2B
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SLC2A1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28419980" target="_blank">PMID:28419980</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We did not detect any pathogenic mutations in SLC2A1 in this cohort. Our data suggests that the frequency of GLUT1 mutations in NAFE is low."</div>
                
                
                <div class="evidence-explanation">The study indicates that no pathogenic mutations in SLC2A1 were found in the cohort, suggesting a low frequency of association with certain types of epilepsy, including Jeavons syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    KCNB1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34070602" target="_blank">PMID:34070602</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Moreover, although there is not enough evidence yet to consider them as candidate for EMA, three more genes present also different alterations in some patients with clinical diagnosis of the disease (SLC2A1, NAA10, and KCNB1)."</div>
                
                
                <div class="evidence-explanation">This review notes KCNB1 alterations in some EMA patients, though evidence is limited.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NAA10
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34070602" target="_blank">PMID:34070602</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Moreover, although there is not enough evidence yet to consider them as candidate for EMA, three more genes present also different alterations in some patients with clinical diagnosis of the disease (SLC2A1, NAA10, and KCNB1)."</div>
                
                
                <div class="evidence-explanation">This review notes NAA10 alterations in some EMA patients, though evidence is limited.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    GABRA1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14631097" target="_blank">PMID:14631097</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"An Ala322Asp mutation in the GABRA1 gene was recently reported to be responsible for causing the autosomal dominant (AD) form of juvenile myoclonic epilepsy (JME) in a French-Canadian family."</div>
                
                
                <div class="evidence-explanation">The abstract does not mention Jeavons syndrome and focuses on juvenile myoclonic epilepsy related to GABRA1 mutations in a different population.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30082241" target="_blank">PMID:30082241</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We identified 30 patients who met the diagnostic criteria of Jeavons syndrome at a single institution..."</div>
                
                
                <div class="evidence-explanation">The study focuses on clinical features and treatment response in Jeavons syndrome without mentioning GABRA1 or a genetic association.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20074235" target="_blank">PMID:20074235</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We have created the Epilepsy Genetic Association Database (epiGAD)..."</div>
                
                
                <div class="evidence-explanation">The database mentions epilepsy genetic association studies but does not specifically address Jeavons syndrome or GABRA1.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Valproic Acid
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">First-line treatment, effective in controlling seizures in many patients.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/6771426" target="_blank">PMID:6771426</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Valproic acid, used alone or in combination with other anticonvulsants in 100 children with epilepsy, improved seizure control in all age groups."</div>
                
                
                <div class="evidence-explanation">The reference supports the efficacy of Valproic Acid in controlling seizures, but it does not specifically mention Jeavons Syndrome or describe it as a first-line treatment.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11393330" target="_blank">PMID:11393330</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Valproic acid controls absences in 75% of patients and also GTCS (70%) and myoclonic jerks (75%); however, it may be undesirable for some women."</div>
                
                
                <div class="evidence-explanation">Valproic acid is mentioned as effective in controlling certain types of seizures common in Jeavons Syndrome (myoclonic jerks), but again it does not specifically refer to Jeavons Syndrome or define it as first-line treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Ethosuximide
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">May be used as an alternative or adjunctive therapy.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17627674" target="_blank">PMID:17627674</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Ethosuximide has a narrow therapeutic profile. It is the drug of choice in the monotherapy or combination therapy of children with generalized absence (petit mal) epilepsy."</div>
                
                
                <div class="evidence-explanation">The reference supports the use of ethosuximide as a treatment for generalized absence epilepsy, which is related to Jeavons syndrome. However, it does not provide specific evidence for its use as an alternative or adjunctive therapy specifically for Jeavons syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Levetiracetam
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">May be used as an alternative or adjunctive therapy.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24798222" target="_blank">PMID:24798222</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This case together with relevant literature data supports the view that the use of levetiracetam might be of benefit for female patients with Jeavons syndrome."</div>
                
                
                <div class="evidence-explanation">The literature mentions the use of levetiracetam resulting in clinical remission for a patient with Jeavons syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20486734" target="_blank">PMID:20486734</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The efficacy of levetiracetam as an adjunctive therapy and as monotherapy for generalized and partial childhood epilepsies and for some types of specific epileptic syndromes of infancy and childhood (such as juvenile myoclonic epilepsy, benign rolandic epilepsy, and Jeavon syndrome) has been..."</div>
                
                
                <div class="evidence-explanation">The literature highlights that levetiracetam can be used as both adjunctive therapy and monotherapy for Jeavons Syndrome among other epileptic syndromes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Avoidance of Provocative Stimuli
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001014" target="_blank">
                            MAXO:0001014
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Patients should avoid photic stimulation that may trigger seizures, such as flickering lights.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14706045" target="_blank">PMID:14706045</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Visually provoked seizures, in particular, can be prevented or treated by avoiding or altering the triggering stimulus. Apart from individual preventive measures (use of specific television or video screens, colored glasses, etc.), prevention and warning on a larger scale are helpful."</div>
                
                
                <div class="evidence-explanation">The literature mentions that avoidance of visually provoking stimuli, like flickering lights, can help in managing photosensitive seizures, though it does not specifically mention Jeavons Syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22946728" target="_blank">PMID:22946728</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Recognized reflex seizure triggers are usually sensory and visual, such as television, discotheques, and video games."</div>
                
                
                <div class="evidence-explanation">This article suggests that visually evoked seizures can be triggered by stimuli like flickering lights, but it does not specifically address Jeavons Syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32861158" target="_blank">PMID:32861158</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome."</div>
                
                
                <div class="evidence-explanation">This directly supports that photic stimulation, such as flickering lights, can trigger seizures in patients with Jeavons Syndrome.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Avoidance of Triggering Stimuli
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001014" target="_blank">
                            MAXO:0001014
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Minimizing exposure to known triggers such as flashing lights or sleep deprivation.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32861158" target="_blank">PMID:32861158</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome"</div>
                
                
                <div class="evidence-explanation">The focus is on the relationship between light stimulation and EEG patterns in Jeavons syndrome, with no mention of avoidance of triggers as a treatment method.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Sunglasses or Blue Light Filtering Glasses
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Wear to reduce light sensitivity and potentially prevent seizures.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14706045" target="_blank">PMID:14706045</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Visually provoked seizures, in particular, can be prevented or treated by avoiding or altering the triggering stimulus. Apart from individual preventive measures (use of specific television or video screens, colored glasses, etc.), prevention and warning on a larger scale are helpful."</div>
                
                
                <div class="evidence-explanation">This reference mentions using colored glasses but does not specifically mention sunglasses or blue light filtering glasses for Jeavons syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30082241" target="_blank">PMID:30082241</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We reviewed and described the epilepsy history, antiepileptic drug trials, and response to treatments."</div>
                
                
                <div class="evidence-explanation">This study focuses on drug treatments and does not mention sunglasses or blue light filtering glasses.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26552567" target="_blank">PMID:26552567</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Jeavons syndrome as an occipital cortex initiated generalized epilepsy."</div>
                
                
                <div class="evidence-explanation">The reference discusses the occipital cortex&#39;s role in Jeavons syndrome but does not mention sunglasses or blue light filtering glasses as a treatment.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">🌍</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Photic Stimulation</div>
                
                
                <div class="item-desc">Exposure to flickering or flashing lights that can trigger seizures in photosensitive individuals.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32861158" target="_blank">PMID:32861158</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome."</div>
                
                
                <div class="evidence-explanation">This study indicates that flashing lights (photic stimulation) are associated with spikes and spike-waves in individuals with Jeavons syndrome, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14706039" target="_blank">PMID:14706039</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In addition to this &#39;transversal&#39; presence of the photosensitive trait across various epilepsy types and diseases, some syndromes in which all, or almost all, seizures are induced by photic stimuli seem to have sufficient specificity and may be considered as syndromes of pure reflex..."</div>
                
                
                <div class="evidence-explanation">The study broadly discusses photosensitive epilepsy and its triggers but does not focus solely on Jeavons Syndrome. It implies a possible link but does not confirm the statement definitively.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28508035" target="_blank">PMID:28508035</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"&#39;We propose that flashing light stimuli can be used as an experimental tool to investigate the visual function and plasticity of neuronal representations and perception after a critical period of neocortical plasticity.&#39;"</div>
                
                
                <div class="evidence-explanation">This study discusses the effects of flashing lights on visual perception and plasticity but does not directly relate to Jeavons Syndrome or its triggering factors.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Sleep Deprivation</div>
                
                
                <div class="item-desc">Insufficient sleep duration or quality that lowers seizure threshold and increases photosensitivity.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28314522" target="_blank">PMID:28314522</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This study demonstrates that photosensitivity is enhanced after awakening from a short sleep following sleep deprivation. Thus, we recommend performing IPS after awakening to increase sensitivity to detect photoparoxysmal epileptiform discharges."</div>
                
                
                <div class="evidence-explanation">This reference indicates that sleep deprivation can enhance photosensitivity in patients, which can be a symptom exacerbation in conditions like Jeavons Syndrome, where photosensitivity is a significant factor.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Jeavons Syndrome
creation_date: &#39;2025-12-04T16:57:31Z&#39;
updated_date: &#39;2025-12-16T03:19:42Z&#39;
description: Jeavons syndrome is a genetic generalized epilepsy characterized by eyelid myoclonia with or without absences, photosensitivity, and eyelid closure-induced seizures. Onset typically occurs in childhood and the condition often persists into adulthood with variable drug responsiveness.
category: Complex
parents:
- Epilepsy
- Neurological Disorder
has_subtypes:
- name: Eyelid Myoclonia with Absences (EMA)
  description: The most common presentation, characterized by eyelid myoclonia with or without absences.
  evidence:
  - reference: PMID:30082241
    supports: SUPPORT
    snippet: &#39;Criteria for Jeavons syndrome included all of the following: (1) eyelid myoclonia with or without absences...&#39;
    explanation: The criteria for diagnosing Jeavons syndrome include eyelid myoclonia with or without absences, supporting the statement&#39;s description.
  - reference: PMID:37329145
    supports: SUPPORT
    snippet: There was consensus that generalized tonic-clonic and absence seizures are typically or occasionally seen in patients.
    explanation: The consensus specifies that absence seizures can be typically or occasionally seen in patients with Jeavons syndrome, supporting the statement.
- name: Eyelid Myoclonia with Absences and Photosensitivity (EMA+)
  description: Eyelid myoclonia with absences that are consistently provoked by photic stimulation.
  evidence:
  - reference: PMID:35394968
    supports: SUPPORT
    snippet: Epilepsy with eyelid myoclonia (EMA) is characterized by eyelid myoclonia, eyelid closure sensitivity, and photosensitivity.
    explanation: This reference confirms that EMA, a defining feature of Jeavons Syndrome, includes photosensitivity as well as eyelid myoclonia and absences.
  - reference: PMID:29722743
    supports: SUPPORT
    snippet: Eyelid myoclonia with absences, generalized tonic-clonic seizures, and severe photosensitivity accompanied by eyelid myoclonia.
    explanation: This case report discusses a patient with Jeavons Syndrome exhibiting eyelid myoclonia with absences and severe photosensitivity, supporting the subtype EMA+ described in the statement.
prevalence:
- subtype: Eyelid Myoclonia with Absences
  population: Global
  percentage: 0.0001
  evidence:
  - reference: PMID:32554361
    supports: REFUTE
    snippet: It is thought to be underdiagnosed rather than have a rare prevalence.
    explanation: The literature suggests that Jeavons syndrome is underdiagnosed instead of being extremely rare, indicating a higher prevalence than 0.0001%.
progression:
- phase: Onset
  subtype: Eyelid Myoclonia with Absences
  age_range: 2-14
  evidence:
  - reference: PMID:32554361
    supports: SUPPORT
    snippet: The mean age at seizure onset was 8.7+/-5.3 years and the mean age at admission to hospital was 17.8+/-10.7 years.
    explanation: This study provides data supporting the age range for seizure onset in Jeavons Syndrome patients, with a mean age of onset fitting within the range of 2 to 14 years.
pathophysiology:
- name: Complex Genetic Predisposition
  description: A complex genetic basis involving multiple genes contributes to susceptibility.
  evidence:
  - reference: PMID:30082241
    supports: SUPPORT
    snippet: Jeavons syndrome is an underreported epileptic syndrome characterized by eyelid myoclonia, eyelid closure-induced seizures or electroencephalography paroxysms, and photosensitivity. Drug-resistant epilepsy is common, but the prognostic factors and clinical course leading to drug resistance have not been well characterized.
    explanation: The abstract discusses drug resistance without specifying a particular genetic basis, but it does imply complexity by mentioning the variability in response to treatments and presence of multiple seizure types.
- name: Neuronal Hyperexcitability
  description: Neurons in the brain exhibit increased excitability, particularly in response to visual stimuli.
  cell_types:
  - preferred_term: Excitatory Glutamatergic Neuron
    description: Neurons that use glutamate as their primary neurotransmitter and mediate excitatory synaptic transmission.
    term:
      id: CL:0000679
      label: glutamatergic neuron
  biological_processes:
  - preferred_term: chemical synaptic transmission
    description: Process of synaptic signaling involving neurotransmitter release and receptor activation.
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  evidence:
  - reference: PMID:21729035
    supports: PARTIAL
    snippet: &#39;We observed two neurophysiologic findings in JS: (1) focal interictal EDs from posterior head region; and (2) predominant focal posterior ictal EDs preceding generalized EDs.&#39;
    explanation: While the study supports an increased excitability of neurons in response to visual stimuli (such as photic stimulation), it does not specifically identify excitatory glutamatergic neurons as the key cell type involved.
  - reference: PMID:31444362
    supports: NO_EVIDENCE
    snippet: The transition from a preictal state to a generalized seizure leads to an abrupt increase in neural activity and connectivity, which is accompanied by a strong alteration in glia-neuron interactions and a massive increase in extracellular glutamate.
    explanation: This study discusses neural activity and connectivity alterations and increased extracellular glutamate during seizures but does not specifically associate these findings with Jeavons Syndrome.
- name: Disrupted Cortical Function
  description: Disruptions in normal brain function, especially in the visual cortex and thalamus, leading to seizures.
  locations:
  - preferred_term: Visual Cortex
    description: Brain region in the occipital lobe responsible for processing visual information.
    term:
      id: UBERON:0000411
      label: visual cortex
  - preferred_term: Thalamus
    description: Central brain structure that relays sensory and motor signals to the cerebral cortex.
    term:
      id: UBERON:0001897
      label: dorsal plus ventral thalamus
  biological_processes:
  - preferred_term: visual perception
    description: Process by which visual stimuli are received and interpreted by the nervous system.
    term:
      id: GO:0007601
      label: visual perception
  evidence:
  - reference: PMID:21729035
    supports: PARTIAL
    snippet: JS has been proposed as idiopathic generalized epilepsy (IGE) because of normal posterior dominant background activity and paroxysmal generalized ictal epileptiform discharges (EDs). However, we noticed subtle occipital EDs preceding EM and interictal posterior EDs using digital video-EEG... Further clinical observations of seizures induced by eye closure, photic stimulation, and hyperventilation along with EEG paroxysms would raise the possibility of the occipital cortex initiating generalized epilepsy network involving the brainstem, and thalamocortical and transcortical pathways in JS.
    explanation: The literature indicates involvement of the occipital cortex and mentions generalized epilepsy networks, which may include the thalamus. However, it does not explicitly support the claim that disruptions in the visual cortex and thalamus are the predominant mechanisms in Jeavons Syndrome.
  - reference: PMID:29880477
    supports: NO_EVIDENCE
    snippet: Largely accepted in the literature is the role the interconnections between the thalamus and cortex play in generalized epilepsy. However, thalamocortical involvement is less understood in focal epilepsy in terms of the effect of seizures on thalamocortical circuitry in the developing brain and subsequent cognitive outcome.
    explanation: This study discusses the role of thalamocortical connections in generalized and focal epilepsy but does not provide specific information on Jeavons Syndrome or its mechanisms.
phenotypes:
- category: Neurologic
  name: Eyelid Myoclonia
  description: Rapid, rhythmic jerking of the eyelids often accompanied by upward eye deviation and brief impairment of consciousness.
  frequency: VERY_FREQUENT
  diagnostic: true
  sequelae:
  - target: Impaired Visual Functioning During Episodes
    description: Transient visual impairment during myoclonic episodes due to involuntary eyelid movement.
    evidence:
    - reference: PMID:8270934
      supports: PARTIAL
      snippet: Brief, typical absences occur with rapid eyelid myoclonia associated with retropulsive movements of the eyeballs and occasionally of the head. The seizures are of shorter duration than in childhood absence epilepsy, and are accompanied by less profound impairment of consciousness.
      explanation: While this reference describes the eyelid movements and consciousness impairment during episodes, it indirectly supports that rapid eyelid closure would impair visual function.
  evidence:
  - reference: PMID:32554361
    supports: SUPPORT
    snippet: Jeavons syndrome (JS) is mainly characterized by eyelid myoclonia with or without absences.
    explanation: The literature supports the neurologic diagnostic of eyelid myoclonia as a high frequency phenotype of Jeavons Syndrome (JS).
  - reference: PMID:30685520
    supports: SUPPORT
    snippet: Eyelid myoclonia, the most common seizure type in all 8 patients, were typically initiated by eating or other simple orofacial stimuli.
    explanation: This study confirms that eyelid myoclonia is a common and significant phenotype of JS, reinforcing the diagnostic.
  - reference: PMID:36216271
    supports: SUPPORT
    snippet: To the best of our knowledge, this is the first case of STAG2 encephalopathy fulfilling all electroclinical criteria for epilepsy with eyelid myoclonia and absences (EMA), formally named Jeavons syndrome (JS).
    explanation: It confirms the diagnostic frequency of eyelid myoclonia as a defining characteristic of JS.
  - reference: PMID:14706039
    supports: PARTIAL
    snippet: Seizures induced by photic (or visual) stimuli or photosensitive seizures can be observed in generalized or focal, idiopathic, or symptomatic epilepsies...
    explanation: While photosensitivity is discussed, the specific association with eyelid myoclonia and its sequelae in JS is not the main focus.
  phenotype_term:
    preferred_term: Eyelid Myoclonia
    description: Rapid, rhythmic jerking of the eyelids often associated with brief impairment of consciousness.
    term:
      id: HP:0011149
      label: Absence seizure with eyelid myoclonia
- category: Neurologic
  name: Absences
  description: Brief episodes of impaired awareness typically lasting seconds, often accompanying eyelid myoclonia.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Absence seizure with eyelid myoclonia
    description: Brief impaired awareness seizures accompanied by eyelid jerking movements.
    term:
      id: HP:0011149
      label: Absence seizure with eyelid myoclonia
  evidence:
  - reference: PMID:15508923
    supports: SUPPORT
    snippet: Eyelid myoclonia and absence.
    explanation: The literature provides a title indicating a connection between eyelid myoclonia (a feature of Jeavons Syndrome) and absences, further supporting the statement.
- category: Neurologic
  name: Generalized Tonic-Clonic Seizures
  description: Convulsive seizures involving bilateral stiffening and rhythmic jerking, occurring in a subset of patients.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Bilateral tonic-clonic seizure with generalized onset
    description: Convulsive seizures with bilateral motor manifestations and generalized onset.
    term:
      id: HP:0025190
      label: Bilateral tonic-clonic seizure with generalized onset
  evidence:
  - reference: PMID:30082241
    supports: PARTIAL
    snippet: After a median follow-up of two years, 80% of patients had drug-resistant epilepsy and 70% experienced generalized tonic-clonic seizures.
    explanation: The statement is partially supported because generalized tonic-clonic seizures occur in 70% of patients, which suggests a high frequency rather than &#39;occasional&#39;.
- category: Cognitive
  name: Mild Cognitive Impairment
  description: Subtle deficits in processing speed, verbal learning, and attention observed in some patients.
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:26492104
    supports: PARTIAL
    snippet: All participants completed neuropsychological evaluations. Statistical analyses revealed performance that was below average on measures of global IQ, processing speed and rote, verbal learning coupled with average nonverbal reasoning, and sustained attention. There was also evidence of impaired higher-level verbal reasoning. While global IQ ranged from low average to borderline impaired, no participant could be accurately described as impaired or having intellectual disability (ID) given the consistently average performance noted on some higher-order tasks including nonverbal reasoning.
    explanation: The literature supports that there are cognitive impairments in Jeavons syndrome, but it does not explicitly classify these impairments as &#39;mild cognitive impairment&#39; (MCI) nor does it mention the frequency as &#39;occasional&#39;. The impairments are more specific and varied, making the statement partially correct but not completely accurate.
- category: Neurologic
  frequency: FREQUENT
  name: Photosensitivity
  description: Abnormal brain response to flickering light or visual patterns that triggers seizures or EEG abnormalities.
  notes: Increased sensitivity to light stimulation, which can provoke seizures or eyelid myoclonia. A common finding in Jeavons syndrome.
  evidence:
  - reference: PMID:30082241
    supports: SUPPORT
    snippet: Jeavons syndrome is an underreported epileptic syndrome characterized by eyelid myoclonia, eyelid closure-induced seizures or electroencephalography paroxysms, and photosensitivity.
    explanation: The abstract clearly states that photosensitivity is a characteristic feature of Jeavons syndrome.
- category: Developmental
  frequency: OCCASIONAL
  name: Developmental Delays
  description: Mildly delayed motor, language, or social milestones occurring in some patients with early seizure onset.
  notes: Mildly delayed motor, language, or social milestones in some patients, especially with early onset of seizures.
  evidence:
  - reference: PMID:30082241
    supports: NO_EVIDENCE
    snippet: &#39;BACKGROUND: Jeavons syndrome is an underreported epileptic syndrome characterized by eyelid myoclonia, eyelid closure-induced seizures or electroencephalography paroxysms, and photosensitivity.&#39;
    explanation: The abstract does not mention developmental delays or any developmental milestones in relation to Jeavons Syndrome.
  - reference: PMID:30683501
    supports: NO_EVIDENCE
    snippet: &#39;Jeavons Syndrome: An Overlooked Epilepsy Syndrome.&#39;
    explanation: The abstract does not provide information on developmental delays or milestones in Jeavons Syndrome.
- name: Impaired Visual Functioning During Episodes
  description: Temporary visual disturbance during seizure activity affecting visual processing and perception.
  frequency: FREQUENT
  evidence:
  - reference: PMID:8270934
    supports: SUPPORT
    snippet: Brief, typical absences occur with rapid eyelid myoclonia associated with retropulsive movements of the eyeballs and occasionally of the head. The seizures are of shorter duration than in childhood absence epilepsy, and are accompanied by less profound impairment of consciousness.
    explanation: The rapid eyelid movements and retropulsive eye movements during seizures directly impair visual function during episodes.
  - reference: PMID:32554361
    supports: SUPPORT
    snippet: Jeavons syndrome (JS) is mainly characterized by eyelid myoclonia with or without absences.
    explanation: The characteristic eyelid myoclonia inherently causes transient visual impairment during episodes due to involuntary eyelid closure.
  phenotype_term:
    preferred_term: Impaired Visual Functioning During Episodes
    description: Transient visual disturbance caused by involuntary eyelid movements during seizure episodes.
    term:
      id: HP:0000572
      label: Visual loss
diagnosis:
- name: EEG with Generalized Spike-and-Wave Patterns
  description: Electroencephalography showing 3-6 Hz generalized spike and polyspike-wave discharges, often triggered by eye closure or photic stimulation.
  presence: Positive
  evidence:
  - reference: PMID:22931943
    supports: SUPPORT
    snippet: Ictal EEG showed 3 - 6 Hz generalized spike and waves and polyspikes burst.
    explanation: The literature supports that the diagnosis of Jeavons Syndrome includes the presence of generalized spike-and-wave patterns in EEG.
genetic:
- name: SYNGAP1
  association: Associated
  notes: Synaptic Ras GTPase-activating protein in NMDA receptor complex; loss-of-function variants reported in EMA cases; implicates excitatory synaptic dysfunction and altered dendritic spine/plasticity.
  evidence:
  - reference: PMID:30541864
    supports: SUPPORT
    snippet: Seizure types included eyelid myoclonia with absences (65%), myoclonic seizures (34%), atypical (20%) and typical (18%) absences, and atonic seizures (14%), triggered by eating in 25%.
    explanation: This large cohort study of 57 SYNGAP1 patients found 65% had eyelid myoclonia with absences, demonstrating strong overlap with Jeavons syndrome phenotype.
  - reference: PMID:34070602
    supports: SUPPORT
    snippet: Based on this, four genes could be associated to this syndrome (SYNGAP1, KIA02022/NEXMIF, RORB, and CHD2).
    explanation: This review identifies SYNGAP1 as one of four candidate genes associated with eyelid myoclonia with absences (Jeavons syndrome).
- name: NEXMIF
  association: Associated
  notes: Also known as KIAA2022; X-linked gene producing EMA-like phenotypes, often pharmacoresistant; female-predominant effects via X-inactivation/mosaicism; synaptic/neurodevelopmental dysfunction from haploinsufficiency.
  evidence:
  - reference: PMID:34070602
    supports: SUPPORT
    snippet: Based on this, four genes could be associated to this syndrome (SYNGAP1, KIA02022/NEXMIF, RORB, and CHD2).
    explanation: This review identifies NEXMIF (KIAA2022) as one of four candidate genes associated with eyelid myoclonia with absences (Jeavons syndrome).
- name: RORB
  association: Associated
  notes: Nuclear receptor involved in neuronal differentiation; alterations reported in some EMA cases; may affect cortical network development/excitability.
  evidence:
  - reference: PMID:34070602
    supports: SUPPORT
    snippet: Based on this, four genes could be associated to this syndrome (SYNGAP1, KIA02022/NEXMIF, RORB, and CHD2).
    explanation: This review identifies RORB as one of four candidate genes associated with eyelid myoclonia with absences (Jeavons syndrome).
- name: CHD2
  association: Associated
  notes: Chromatin remodeling dysfunction may perturb neuronal gene expression and cortical excitability; variants observed in EMA cases with GTCS comorbidity.
  evidence:
  - reference: PMID:26262932
    supports: PARTIAL
    snippet: Conversely, CHD2 could be responsible for a proper phenotype characterized by infantile-onset generalized epilepsy, intellectual disability, and photosensitivity, which might overlap with MAE, Lennox-Gastaut, Dravet, and Jeavons syndromes.
    explanation: The literature indicates that CHD2 mutations may overlap with phenotypes seen in Jeavons Syndrome, but it does not specifically state a direct genetic association exclusive to Jeavons Syndrome.
  - reference: PMID:34070602
    supports: SUPPORT
    snippet: Based on this, four genes could be associated to this syndrome (SYNGAP1, KIA02022/NEXMIF, RORB, and CHD2).
    explanation: This review identifies CHD2 as one of four candidate genes associated with eyelid myoclonia with absences (Jeavons syndrome).
- name: CSNK2B
  association: Associated
  notes: Casein kinase 2 beta; de novo missense variant reported in child with eyelid myoclonia; influences neuronal development and Wnt/β-catenin signaling; proposed novel candidate gene.
- name: SLC2A1
  association: Associated
  notes: GLUT1 glucose transporter; rare EMA reports suggest metabolic contributions in some patients; impaired glucose transport can alter neuronal metabolism and seizure threshold.
  evidence:
  - reference: PMID:28419980
    supports: REFUTE
    snippet: We did not detect any pathogenic mutations in SLC2A1 in this cohort. Our data suggests that the frequency of GLUT1 mutations in NAFE is low.
    explanation: The study indicates that no pathogenic mutations in SLC2A1 were found in the cohort, suggesting a low frequency of association with certain types of epilepsy, including Jeavons syndrome.
- name: KCNB1
  association: Associated
  notes: Voltage-gated potassium channel Kv2.1; rare variants reported in EMA-like presentations; perturbation can change neuronal repolarization and network excitability.
  evidence:
  - reference: PMID:34070602
    supports: PARTIAL
    snippet: Moreover, although there is not enough evidence yet to consider them as candidate for EMA, three more genes present also different alterations in some patients with clinical diagnosis of the disease (SLC2A1, NAA10, and KCNB1).
    explanation: This review notes KCNB1 alterations in some EMA patients, though evidence is limited.
- name: NAA10
  association: Associated
  notes: N-terminal acetyltransferase; rare EMA reports; N-terminal acetylation defects could impact multiple neuronal proteins and circuit development.
  evidence:
  - reference: PMID:34070602
    supports: PARTIAL
    snippet: Moreover, although there is not enough evidence yet to consider them as candidate for EMA, three more genes present also different alterations in some patients with clinical diagnosis of the disease (SLC2A1, NAA10, and KCNB1).
    explanation: This review notes NAA10 alterations in some EMA patients, though evidence is limited.
- name: GABRA1
  association: Associated
  evidence:
  - reference: PMID:14631097
    supports: REFUTE
    snippet: An Ala322Asp mutation in the GABRA1 gene was recently reported to be responsible for causing the autosomal dominant (AD) form of juvenile myoclonic epilepsy (JME) in a French-Canadian family.
    explanation: The abstract does not mention Jeavons syndrome and focuses on juvenile myoclonic epilepsy related to GABRA1 mutations in a different population.
  - reference: PMID:30082241
    supports: NO_EVIDENCE
    snippet: We identified 30 patients who met the diagnostic criteria of Jeavons syndrome at a single institution...
    explanation: The study focuses on clinical features and treatment response in Jeavons syndrome without mentioning GABRA1 or a genetic association.
  - reference: PMID:20074235
    supports: NO_EVIDENCE
    snippet: We have created the Epilepsy Genetic Association Database (epiGAD)...
    explanation: The database mentions epilepsy genetic association studies but does not specifically address Jeavons syndrome or GABRA1.
environmental:
- name: Photic Stimulation
  description: Exposure to flickering or flashing lights that can trigger seizures in photosensitive individuals.
  synonyms:
  - Flashing Lights
  effect: Triggering Factor
  evidence:
  - reference: PMID:32861158
    supports: SUPPORT
    snippet: Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome.
    explanation: This study indicates that flashing lights (photic stimulation) are associated with spikes and spike-waves in individuals with Jeavons syndrome, supporting the statement.
  - reference: PMID:14706039
    supports: PARTIAL
    snippet: In addition to this &#39;transversal&#39; presence of the photosensitive trait across various epilepsy types and diseases, some syndromes in which all, or almost all, seizures are induced by photic stimuli seem to have sufficient specificity and may be considered as syndromes of pure reflex photosensitive epilepsy.
    explanation: The study broadly discusses photosensitive epilepsy and its triggers but does not focus solely on Jeavons Syndrome. It implies a possible link but does not confirm the statement definitively.
  - reference: PMID:28508035
    supports: NO_EVIDENCE
    snippet: &#39;&#39;&#39;We propose that flashing light stimuli can be used as an experimental tool to investigate the visual function and plasticity of neuronal representations and perception after a critical period of neocortical plasticity.&#39;&#39;&#39;
    explanation: This study discusses the effects of flashing lights on visual perception and plasticity but does not directly relate to Jeavons Syndrome or its triggering factors.
  exposure_term:
    preferred_term: Light exposure
    description: Exposure to visible light, particularly flickering or patterned stimuli that can provoke seizures.
    term:
      id: XCO:0000284
      label: controlled visible light exposure
- name: Sleep Deprivation
  description: Insufficient sleep duration or quality that lowers seizure threshold and increases photosensitivity.
  effect: Exacerbates Symptoms
  exposure_term:
    preferred_term: Sleep deprivation
    description: Restriction or deprivation of sleep that increases seizure susceptibility.
    term:
      id: XCO:0001069
      label: sleep restriction
  evidence:
  - reference: PMID:28314522
    supports: SUPPORT
    snippet: This study demonstrates that photosensitivity is enhanced after awakening from a short sleep following sleep deprivation. Thus, we recommend performing IPS after awakening to increase sensitivity to detect photoparoxysmal epileptiform discharges.
    explanation: This reference indicates that sleep deprivation can enhance photosensitivity in patients, which can be a symptom exacerbation in conditions like Jeavons Syndrome, where photosensitivity is a significant factor.
treatments:
- name: Valproic Acid
  role: Anticonvulsant
  description: First-line treatment, effective in controlling seizures in many patients.
  evidence:
  - reference: PMID:6771426
    supports: PARTIAL
    snippet: Valproic acid, used alone or in combination with other anticonvulsants in 100 children with epilepsy, improved seizure control in all age groups.
    explanation: The reference supports the efficacy of Valproic Acid in controlling seizures, but it does not specifically mention Jeavons Syndrome or describe it as a first-line treatment.
  - reference: PMID:11393330
    supports: PARTIAL
    snippet: Valproic acid controls absences in 75% of patients and also GTCS (70%) and myoclonic jerks (75%); however, it may be undesirable for some women.
    explanation: Valproic acid is mentioned as effective in controlling certain types of seizures common in Jeavons Syndrome (myoclonic jerks), but again it does not specifically refer to Jeavons Syndrome or define it as first-line treatment.
  treatment_term:
    preferred_term: pharmacotherapy
    description: First-line anticonvulsant treatment using valproic acid for seizure control.
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Ethosuximide
  role: Anticonvulsant
  description: May be used as an alternative or adjunctive therapy.
  evidence:
  - reference: PMID:17627674
    supports: PARTIAL
    snippet: Ethosuximide has a narrow therapeutic profile. It is the drug of choice in the monotherapy or combination therapy of children with generalized absence (petit mal) epilepsy.
    explanation: The reference supports the use of ethosuximide as a treatment for generalized absence epilepsy, which is related to Jeavons syndrome. However, it does not provide specific evidence for its use as an alternative or adjunctive therapy specifically for Jeavons syndrome.
  treatment_term:
    preferred_term: pharmacotherapy
    description: Anticonvulsant treatment primarily targeting absence seizures.
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Levetiracetam
  role: Anticonvulsant
  description: May be used as an alternative or adjunctive therapy.
  evidence:
  - reference: PMID:24798222
    supports: SUPPORT
    snippet: This case together with relevant literature data supports the view that the use of levetiracetam might be of benefit for female patients with Jeavons syndrome.
    explanation: The literature mentions the use of levetiracetam resulting in clinical remission for a patient with Jeavons syndrome.
  - reference: PMID:20486734
    supports: SUPPORT
    snippet: The efficacy of levetiracetam as an adjunctive therapy and as monotherapy for generalized and partial childhood epilepsies and for some types of specific epileptic syndromes of infancy and childhood (such as juvenile myoclonic epilepsy, benign rolandic epilepsy, and Jeavon syndrome) has been demonstrated.
    explanation: The literature highlights that levetiracetam can be used as both adjunctive therapy and monotherapy for Jeavons Syndrome among other epileptic syndromes.
  treatment_term:
    preferred_term: pharmacotherapy
    description: Broad-spectrum anticonvulsant that may be used as alternative or adjunctive therapy.
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Avoidance of Provocative Stimuli
  description: Patients should avoid photic stimulation that may trigger seizures, such as flickering lights.
  evidence:
  - reference: PMID:14706045
    supports: PARTIAL
    snippet: Visually provoked seizures, in particular, can be prevented or treated by avoiding or altering the triggering stimulus. Apart from individual preventive measures (use of specific television or video screens, colored glasses, etc.), prevention and warning on a larger scale are helpful.
    explanation: The literature mentions that avoidance of visually provoking stimuli, like flickering lights, can help in managing photosensitive seizures, though it does not specifically mention Jeavons Syndrome.
  - reference: PMID:22946728
    supports: PARTIAL
    snippet: Recognized reflex seizure triggers are usually sensory and visual, such as television, discotheques, and video games.
    explanation: This article suggests that visually evoked seizures can be triggered by stimuli like flickering lights, but it does not specifically address Jeavons Syndrome.
  - reference: PMID:32861158
    supports: SUPPORT
    snippet: Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome.
    explanation: This directly supports that photic stimulation, such as flickering lights, can trigger seizures in patients with Jeavons Syndrome.
  - reference: PMID:29555355
    supports: SUPPORT
    snippet: Self-induced seizures were predominantly eyelid myoclonia +/- absences... EEG demonstrated a normal background with 3-4 Hz spike waves +/- polyspike waves as well as a photoparoxysmal response.
    explanation: This reference indicates that photic stimulation can induce seizures in patients with Jeavons Syndrome, thus supporting the need to avoid such stimuli.
  treatment_term:
    preferred_term: medical action avoidance
    description: Behavioral intervention to avoid exposure to known seizure triggers.
    term:
      id: MAXO:0001014
      label: medical action avoidance
- name: Avoidance of Triggering Stimuli
  description: Minimizing exposure to known triggers such as flashing lights or sleep deprivation.
  evidence:
  - reference: PMID:32861158
    supports: NO_EVIDENCE
    snippet: Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome
    explanation: The focus is on the relationship between light stimulation and EEG patterns in Jeavons syndrome, with no mention of avoidance of triggers as a treatment method.
  treatment_term:
    preferred_term: medical action avoidance
    description: Lifestyle modification to minimize exposure to photic and other seizure triggers.
    term:
      id: MAXO:0001014
      label: medical action avoidance
- name: Sunglasses or Blue Light Filtering Glasses
  description: Wear to reduce light sensitivity and potentially prevent seizures.
  evidence:
  - reference: PMID:14706045
    supports: NO_EVIDENCE
    snippet: Visually provoked seizures, in particular, can be prevented or treated by avoiding or altering the triggering stimulus. Apart from individual preventive measures (use of specific television or video screens, colored glasses, etc.), prevention and warning on a larger scale are helpful.
    explanation: This reference mentions using colored glasses but does not specifically mention sunglasses or blue light filtering glasses for Jeavons syndrome.
  - reference: PMID:30082241
    supports: NO_EVIDENCE
    snippet: We reviewed and described the epilepsy history, antiepileptic drug trials, and response to treatments.
    explanation: This study focuses on drug treatments and does not mention sunglasses or blue light filtering glasses.
  - reference: PMID:26552567
    supports: NO_EVIDENCE
    snippet: Jeavons syndrome as an occipital cortex initiated generalized epilepsy.
    explanation: The reference discusses the occipital cortex&#39;s role in Jeavons syndrome but does not mention sunglasses or blue light filtering glasses as a treatment.
  - reference: PMID:32861158
    supports: NO_EVIDENCE
    snippet: Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome.
    explanation: This reference discusses EEG characteristics in Jeavons syndrome without mentioning sunglasses or blue light filtering glasses as a treatment.
  treatment_term:
    preferred_term: supportive care
    description: Use of protective eyewear to reduce light-induced seizure triggers.
    term:
      id: MAXO:0000950
      label: supportive care
disease_term:
  preferred_term: eyelid myoclonia with absences
  description: A genetic generalized epilepsy syndrome characterized by eyelid myoclonia, photosensitivity, and eye closure-induced seizures.
  term:
    id: MONDO:0015346
    label: epilepsy with eyelid myoclonia
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Jeavons_Syndrome.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>